Praetego is a preclinical stage pharmaceutical company committed to protecting patients from the chronic diseases of aging, starting with Alzheimer’s Disease.
Praetego’s first-in-class small molecule series, the Amadorins, possess a multi-functional mechanism that inhibits early drivers of pathology leading to neurodegeneration and serious diabetic complications. Animal and safety data supports the application of our candidates to limit Alzheimer’s Disease (AD), Diabetic Neuropathy (DPN), and Diabetic Retinopathy (DR). We are focused on Alzheimer’s Disease and in bringing our lead candidate to clinic as a fundamental alternative to current options.
Praetego’s first-in-class small molecule series, the Amadorins, possess a multi-functional mechanism that inhibits early drivers of pathology leading to neurodegeneration and serious diabetic complications. Animal and safety data supports the application of our candidates to limit Alzheimer’s Disease (AD), Diabetic Neuropathy (DPN), and Diabetic Retinopathy (DR). We are focused on Alzheimer’s Disease and in bringing our lead candidate to clinic as a fundamental alternative to current options.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
PTG-630
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
